Submitted by Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, was awarded the MassEcon Gold Award for Economic Impact in the Northeast region for their outstanding contributions to the Massachusetts economy.
MassEcon, the state’s private sector partner in promoting business growth in Massachusetts, selects a small number of recipients based on job growth, facility expansion and investment, community involvement, and commitment to diversity, inclusion, and equity initiatives. With its new, state-of-the-art Gene Therapy Manufacturing Facility in Bedford, along with its research and administrative offices in Woburn and Somerville, Ultragenyx employs more than 260 employees in the state and fosters a strong company culture that is committed to the mission of transforming the lives of people living with rare diseases.
“We are proud to be part of the thriving life-sciences community here in Massachusetts that enhances our ability to develop leading-edge therapeutics for individuals living with rare diseases,” said Dennis Huang, chief technical operations officer and executive vice president, Gene Therapy Research and Development. “We are grateful for the support from state officials, along with local officials from Bedford, Woburn, and Somerville, that allowed us to build and operate facilities across the Commonwealth to manufacture life-changing medicines for rare families in need. Thank you, MassEcon, for recognizing our contributions to this valuable ecosystem.”
Ultragenyx was honored at MassEcon’s awards ceremony on April 11 at Gillette Stadium in Foxborough. For more information about this recognition, click here.
Loading ...
